Posters

  • E Ruiz-Del-Yerro, P Soblechero-Martin, I Larrañaga, E Albiasu-Arteta, V Arechavala-Gomeza “Myoblots for the evaluation of new treatments in neuromuscular disorders” International Congress on Neuromuscular Disorders. Vienna, Austria. July 2018 (Journal of Neuromuscular Disorders, vol. 5, no. s1, pp. S1-S408, 2018 https://doi.org/10.3233/JND-189001
  • P Soblechero-Martin, I García-Jiménez, E Ruiz-Del-Yerro, E Albiasu-Arteta, V Arechavala-Gomeza “CRISPR/Cas gene editing in Duchenne muscular dystrophy cultures to test new treatments for the disease” International Congress on Neuromuscular Disorders. Vienna, Austria. July 2018 (Journal of Neuromuscular Disorders, vol. 5, no. s1, pp. S1-S408, 2018 https://doi.org/10.3233/JND-189001
  • Soblechero-Martín, E. Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza. “Terapias Avanzadas para Enfermedades Neuromusculares” Science + ERA Career Day, Bilbao, Spain Sept 2017
  • Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza “Myo-cytoblots: quantification of dystrophin by in-cell western assay for a streamlined development of DMD treatments” Action Duchenne International conference. London, United Kingdom. November 2016 AWARD WINNING POSTER
  • García-Jimenez, E. Ruiz-Del-Yerro, V. Arechavala-Gomeza “Selection of reference genes for normalisation of dystrophin mRNA RT-qPCR data” Action Duchenne International conference. London, United Kingdom. November 2016
  • Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza “Myo-cytoblots: quantification of dystrophin by in-cell western assay for a streamlined development of DMD treatments” 21st International Congress of the World Muscle Society 2016, Granada, Spain (Neuromuscular Disorders, Vol. 26, S159 http://dx.doi.org/10.1016/j.nmd.2016.06.267 )
  • García-Jimenez, E. Ruiz-Del-Yerro, V. Arechavala-Gomeza “Selection of reference genes for normalisation of dystrophin mRNA RT-qPCR data” 21st International Congress of the World Muscle Society 2016, Granada, Spain (Neuromuscular Disorders, Vol. 26, S159–S160)
  • Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza “Myo-cytoblots: a method to quantify of dystrophin by in-cell western assay to accelerate preclinical assessment of DMD treatments” Neurogune June 2016 , Bilbao, Spain
  • Hiller, M.S. Falzarano, I. Garcia, Rudie Weij, V. Sardone, L. Popplewell, E. Ruiz-Del-Yerro, K. Anthony, R. Verheul, J Morgan, G. Dickson, F. Muntoni, A. Aartsma-Rus, A. Ferlini, V. Arechavala-Gomeza, et al. “Multicenter quantification of dystrophin exon 51 skipping” 11th Annual Meeting Oligonucleotide Therapeutics Society, October 2015, Leiden, Netherlands
  • Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza. “Quantifying dystrophin in cell culture: a method to accelerate preclinical assessment of DMD treatments” 20th International Congress of the World Muscle Society 2015, Brighton, UK. Neuromuscular Disorders, (October 2015,Volume 25, Supplement 2, Page S254, http://dx.doi.org/10.1016/j.nmd.2015.06.251 )
  • Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza “Terapias avanzadas para enfermedades Neuromusculares” Science + (ORGANISED BY CERU/SRUK) May 2015
  • Torelli, K Anthony, V Arechavala-Gomeza, et al. UK “Towards a consensus on biochemical outcome measures for Duchenne muscular dystrophy clinical trials” Neuromuscular Translational Research Conference 2014, London, UK Neuromuscular disorders (March 2014 Volume 24, Supplement 1, Page S11
  • V Arechavala-Gomeza, C Godfrey, A Hibbert et al. “Optimising novel imaging methods to quantify low levels of dystrophin in Duchenne muscular dystrophy” UK Neuromuscular Translational Research Conference 2013, Oxford, UK
  • K Anthony, V Arechavala-Gomeza et al. “Biochemical and Clinical Variability of Becker Muscular Dystrophy: Predicting Optimal Target Exons for Exon Skipping Therapy in Duchenne Muscular Dystrophy”17th International Congress of the World Muscle Society 2012, Perth, Australia, Neuromuscular Disorders Vol. 22, Issue 9, Page 862
  • L Popplewell, V Arechavala-Gomeza, et al (2012). The next DMD exon skipping trial: selection of AO target. 5th UK Neuromuscular Translational Research Conference Newcastle, UK March 2012 Neuromuscular Disorders Vol. 22Supplement 1, Pages S9-S10
  • K Anthony, S Cirak, S Torelli, G Tasca, L Feng, V Arechavala-Gomeza, et al “Correlation of internally deleted dystrophin and dystrophin-associated protein expression with clinical severity in Becker muscular dystrophy” 5th UK Neuromuscular Translational Research Conference Newcastle, UK March 2012 Neuromuscular Disorders Vol. 22 Supplement 1, Page S7
  • S Cirak, V Arechavala-Gomeza, et al Exon skipping and dystrophin restoration in Duchenne Muscular Dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment. 9th European Paediatric Neurology Society Congress Dubrovnik, Croatia May 2011
  • S Cirak, V Arechavala-Gomeza et al. Exon skipping and dystrophin restoration in Duchenne Muscular Dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment. 4rd UK Neuromuscular Translational Research Conference London, UK April 2011 PUBLICATION: Neuromuscular Disorders March 2011 (Vol. 21Supplement 1, Pages S7-S8)
  • Cirak; L. Feng; S. Torelli; V. Arechavala-Gomeza; et al Induction of dystrophin in DMD patients by antisense oligonucleotide AVI-4658 restores the dystrophin glycoprotein complex 15th International Congress of the World Muscle Society 2010, Kumamoto, Japan Neuromuscular Disorders October 2010 (Vol 20, Page 643) http://www.sciencedirect.com/science/article/pii/S0960896610004219
  • S Cirak, Feng, L,V Arechavala-Gomeza et al. “Induction of dystrophin in DMD patients by antisense oligonucleotide AVI-4658 restores the dystrophin glycoprotein complex”. 3rd UK Neuromuscular Translational Research Conference Oxford, UK March 2010 PUBLICATION: Neuromuscular Disorders March 2010 (Vol. 20 Supplement 6)
  • Malerba, P. Sharp, IR Graham, V Arechavala-Gomeza, K Foster, JE Morgan, F Muntoni, D Wells, G Dickson “Chronic long term administration of phosphorodiamidate morpholino oligomer profoundly ameliorates activity, muscle strength and phenotype in , dystrophic mdx mice” 3rd UK Neuromuscular Translational Research Conference Oxford, UK March 2010 PUBLICATION: Neuromuscular Disorders March 2010 (Vol. 20 Supplement S12)
  • Jihee Kim, Arechavala-Gomeza V, Muntoni F. The characterisation of out of frame duplications in DMD patients UK Neuromuscular Translational Research Conference 2010, Oxford, United Kingdom March 2010 Neuromuscular Disorders 20 (pp. S5) http://www.sciencedirect.com/science/article/pii/S0960896610700183
  • Malerba, P. Sharp, IR Graham, V Arechavala-Gomeza, K Foster, JE Morgan, F Muntoni, D Wells, G Dickson “Clinically Applicable Dosing Regimens of Phosphorodiamidate Morpholino Oligomer Profoundly Improve Behaviour, Activity, and Dystrophic phenotype in mdx mice” 7th Annual Conference of the British Society for Gene Therapy, Egham, England, UK, March 2010, Human Gene Therapy, Mary Ann Liebert  Inc, 508 – 508
  • Arechavala-Gomeza, on behalf of the MDEX consortium Developing and delivering antisense strategies for Duchenne muscular dystrophy. TREAT-NMD International Conference 2009 Brussels, Belgium, December 2009
  • Arechavala-Gomeza, et al Measuring restored dystrophin in treated muscle: An immunohistological intensity measurement method 14th International Congress of the World Muscle Society Neuromuscular Disorders (Vol. 19, Issue 8, Page 615) Geneva, Switzerland September 2009
  • V Arechavala-Gomeza, et al. Measuring restored dystrophin in treated muscle: An immunohistological intensity measurement method UK Neuromuscular Translational Research Conference 2009 Newcastle, United Kingdom May 2009
  • Kinali, V. Arechavala-Gomeza, et al. Establishing the parameters for clinical trials of antisense oligonucleotide therapy in Duchenne muscular dystrophy 13th International Congress of the World Muscle Society 2008 Neuromuscular Disorders (Vol. 18, Issue 9, Page 773), Newcastle, United Kingdom, October 2008
  • C Adkin, V. Arechavala-Gomeza, et al. “A model of human muscle regeneration in vivo to test potential therapies for DMD” 13th International Congress of the World Muscle Society 2008 Neuromuscular Disorders (Vol. 18, Issue 9, Page 759), Newcastle, United Kingdom, October 2008
  • Kinali, V. Arechavala-Gomeza, et al. Establishing the parameters for clinical trials of antisense oligonucleotide therapy in Duchenne muscular dystrophy British Paediatric Neurology Association conference 2008, Leeds, UK Developmental Medicine & Child Neurology 50, 6-32
  • Arechavala-Gomeza, Maria Kinali et al Do revertants increase with age in Duchenne muscular dystrophy boys? 12th International Congress of the World Muscle Society 2007 Neuromuscular Disorders (Vol. 17, Issue 9, Page 842), Sicily, Italy ,October 2007
  • Arechavala-Gomeza, Bushby, K., Dickson, G., Graham, I., Kinali, M., Liu, K., Yin, H. A phase I/II clinical trial in Duchenne muscular dystrophy using IM and IV delivered antisense oligonucleotides: The MDEX consortium 11th International Congress of the World Muscle Society 2006, Brugges, Belgium Neuromuscular Disorders (Vol. 17, Issue 9, Page 842) October 2006 10.1016/j.nmd.2006.05.138
  • Arechavala-Gomeza, et al. SOD 1 mutant proteins misfolding and aggregation. Implications of dimerization and metal deficiency 2nd Meeting of the European ALS/MND Consortium, Nice, France, April 2004
  • Arechavala-Gomeza V, et al. SOD1 mutant proteins misfolding and aggregation: implications of dimerization 14th International Symposium on ALS/MND, (Milan, Italy), ALS and other motor neuron disorders 2003 4 (Suppl 1), 79–96, October 2003

Comments are closed.